First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial
| Autor: | Baas, Paul a, *, Scherpereel, Arnaud b, Nowak, Anna K c, d, Fujimoto, Nobukazu e, Peters, Solange f, Tsao, Anne S g, Mansfield, Aaron S h, Popat, Sanjay i, j, Jahan, Thierry k, Antonia, Scott l, Oulkhouir, Youssef m, Bautista, Yolanda n, Cornelissen, Robin o, Greillier, Laurent p, Grossi, Francesco q, Kowalski, Dariusz r, Rodríguez-Cid, Jerónimo s, Aanur, Praveen t, Oukessou, Abderrahim t, Baudelet, Christine t, Zalcman, Gérard u |
|---|---|
| Zdroj: | In The Lancet 30 January-5 February 2021 397(10272):375-386 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|